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This study analysed mRNA expression of two members of the methyl-CpG-binding protein family – MeCP2 and MBD2 – in human
non-neoplastic (n¼11) and neoplastic (n¼57) breast tissue specimens using a quantitative real-time PCR method. We observed
higher expression levels of MeCP2 mRNA in neoplastic tissues than in non-neoplastic tissues (P¼0.001), whereas no significant
differences for MBD2 were detected. When studying the relations between the most important clinicopathologic features of breast
cancer and the mRNA expression level of both MBDs, we found that oestrogen receptor (OR)-positive breast cancer specimens
contained higher levels of MeCP2 mRNA than did OR-negative cancers (P¼0.005). Furthermore, we observed statistically
significantly higher levels of MeCP2 in non-neoplastic tissues expressing high levels of OR as compared to those expressing low levels
(P¼0.017). Finally, using a linear regression model, we identified a statistically significant association between OR expression and
MeCP2 mRNA expression in neoplastic and non-neoplastic breast tissue specimens (P¼0.003). In conclusion, we were able to
demonstrate for the first time that there exists a strong association between OR status and MeCP2 mRNA expression. Furthermore,
we speculate that MeCP2, regulated by OR, plays a key role in the differentiation processes in human breast tissues.
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Changes in the DNA methylation status are one of the most
common molecular alterations in human neoplasia. Hypermethy-
lation of CpG islands, especially when located in the promoter
region, generally causes a loss of expression on the part of genes
possessing this structure at their 50 end (Jones and Baylin, 2002;
Laird, 2003; Mu ¨ller and Widschwendter, 2003). The so-called
methyl-CpG-binding proteins (MBDs) are important constituents
of the DNA methylation machinery, since they are directly
involved in mediating the epigenetic signal (Bird and Wolffe,
1999). The five MBD proteins known to date share a conserved
methyl-CpG-binding domain (MBD), which is 70–75 amino acids
in length and exhibits 50–70% similarity between the proteins.
Four of them are associated with the transcriptional repression of
methylated templates in vertebrates and bind methylated DNA
(Wade, 2001). MeCP2 is the best studied member of the MBD
family: MeCP2 is an abundant chromosome-binding protein that
selectively binds 5-methyl cytosine residues in symmetrically
positioned CpG dinucleotides in the mammalian genome (Lewis
et al, 1992). MeCP2 contains two functional domains, an 85-
amino-acid MBD essential for its binding to 5-methylcytosine
(Nan et al, 1993), and a 104-amino-acid transcriptional repression
domain (TRD) that interacts with histone deacetylase and the
transcriptional corepressor Sin3A.
In addition to MeCP2, MBD2 is another family member already
studied in human neoplasia (Kanai et al, 1999; Billard et al, 2002).
MeCP2 and MBD2 differ in several ways with regard to their
binding capacities: MeCP2 can recognise a single symmetrically
methylated CpG (Meehan et al, 1992). MBD2 can bind, in vitro,t o
DNA sequences containing a few methylated CpGs (Hendrich and
Bird, 1998); however, the MeCP1 complex containing this protein
binds only to densely methylated DNA (Meehan et al, 1989).
Invalidation of MeCP2 in mice indicates that MeCP1 cannot
compensate for the absence of MeCP2 (Chen et al, 2001; Guy et al,
2001), and, conversely, invalidation of MBD2 does not prompt the
neurological disorders observed in MeCP2-null mice mutants
(Hendrich et al, 2001). The absence of compensation between
these proteins suggests that these two MBDs play specific roles in
cellular physiology. Although the expression patterns of the MBDs
are not yet fully determined, it has been shown in mouse and rat
that these genes are expressed at various levels depending on the
cell type and the differentiation state (Tate et al, 1996). In adult
rodent somatic tissues, MeCP2 expression level varies between
tissues. For example, the brain has the highest level and the testis
the lowest (Meehan et al, 1992).
In addition to the loss of MBD2 and MeCP2 in human cancers
(Mu ¨ller-Tidow et al, 2001), it has been shown in colon cancer cell
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ylines that MBD2 is associated with methylated promoters of silent
p14/p16 gene, and this methylation-dependent association seems
to be responsible for their silencing (Magdinier and Wolffe, 2001).
Only one study concentrated on the expression levels of MBD2 and
MeCP2 in human breast cancer, indicating a loss of MBD2
expression in breast cancer specimens, but no alteration of the
expression level of MeCP2 (Billard et al, 2002). Moreover, an
upregulation of MBD2 and MeCP2 has been described during
differentiation in foetal breast tissue (Billard et al, 2002).
Breast cancer is the most common malignancy among women in
most Western countries. Oestrogen receptor a (OR-a) is a ligand-
activated nuclear receptor that regulates the transcription of
oestrogen-responsive genes in diverse target cells (Govind and
Thampan, 2001). Oestrogen receptor alpha expression and
activation through oestrogens have long been linked to mammary
carcinogenesis, breast tumour progression and outcome of breast
cancer patients (Fishman et al, 1995). Approximately two-third of
breast cancers express the OR gene and synthesise OR protein.
These tumours tend to be more differentiated and are often
responsive to endocrine therapy. One-third of all breast cancers
lack the OR and these tumours are generally associated with
poorer histological differentiation, higher growth fraction and
somewhat worse clinical outcome than OR-positive breast cancers
(McGuire, 1978). Therefore, OR can be designated as a surrogate
marker for better differentiation of breast cancer tissue.
In order to gain a better insight into the involvement of MBDs in
breast cancer, we investigated the expression levels of MeCP2 and
MBD2 in human non-neoplastic and neoplastic breast tissue in
general using quantitative real-time PCR. We also addressed the
question of whether any relations exist between the most
important clinicopathologic features of breast cancer and the
expression levels of MeCP2 and MBD2.
We were able to demonstrate that there exists a strong
association between OR status and the MeCP2 mRNA expression.
We speculate that MeCP2, which is one of the most important
mediators of the epigenetic signal, is regulated by OR and therefore




Breast cancer specimens (n¼57) and non-neoplastic breast tissue
(n¼11) were obtained immediately after resection of the breast or
lumpectomy at the Department of Obstetrics and Gynecology,
University Hospital of Innsbruck. Specimens were brought to our
pathologist, and a part of the tissue was placed into liquid nitrogen
and stored at  701C until lyophilisation.
Of the 11 non-neoplastic specimens, five (46%) were diagnosed
as fibroadenomas, two (18%) as papillomatosis and four (36%) as
fibrocystic disease (grades I–III). The mean age at diagnosis of
this group of patients was 43.7 years. Of the 57 breast cancer
patients, 12 (21%) patients were diagnosed with pT I, 41 (72%)
with pT II, two (3.5%) with pT III and two (3.5%) with pT IV of the
disease. A total of 25 (44%) patients were nodal negative and 32
(56%) patients nodal positive. These included 40 (70%) invasive
ductal carcinomas, eight (14%) lobular carcinomas and nine (16%)
carcinomas otherwise differentiated (medullary, mucinous, papil-
lary and tubular carcinomas). Oestrogen receptor and progester-
one receptor (PR) status were identified immunohistochemically
and/or biochemically. In all, 18 (32%) cancer specimens were
hormone receptor negative, while 39 (68%) were hormone receptor
positive (defined as OR and/or PR positive): 18 (32%) were OR and
PR negative, two (3%) were OR negative and PR positive, four
(7%) were OR positive and PR negative and 33 (58%) were OR and
PR positive. The mean age at diagnosis of this group of patients
was 62.9 years.
RNA extraction and RT reaction
Total cellular RNA was extracted from the tumour specimens using
the acid guanidium thiocyanate–phenol–chloroform method as
recently described (Widschwendter et al, 2000). Integrity was
evaluated by assessing the 18S- and 28S-ribosomal RNA bands in
2% ethidium bromide-stained agarose gel. RNA concentration was
measured by spectrophotometric analysis. For PR mRNA expres-
sion analysis, total RNA was treated with deoxyribonuclease to
remove any contaminating genomic DNA.
DNase treatment of RNA was performed in a final volume of
30ml containing 1  RT-Buffer (50mM Tris-HCl, pH 8.3, 75mM
KCl, 5mM MgCl2), 10U of rRNasin
s RNase Inhibitor (Promega,
Madison, WI, USA), 20U of RNase-free DNase (Boehringer
Mannheim, 7767852, Mannheim, Germany) and 4mg of isolated
RNA. After the addition of DNase, the mix was incubated for
60min at 371C and inactivated at 951C for 10min.
Reverse transcription of RNA was performed in a final volume
of 20ml containing 1  RT-Buffer (50mM Tris-HCl, pH 8.3, 75mM
KCl, 5mM MgCl2), 40U of rRNasin
s RNase Inhibitor (Promega,
Madison, WI, USA), 10mM dithiothreitol, 200U of M-MLV
Reverse Transcriptase (Gibco BRL, Gaithersburg, MD, USA),
5mM random hexamers (Applied Biosystems, Foster City, CA,
USA) and 400ng of total RNA. The samples were first incubated at
651C for 5min and then quick-chilled on ice. After adding the M-
MLV enzyme, the samples were incubated at 251C for 10min and
at 371C for 50min, followed by a period of 15min at 701Ct o
inactivate the reverse transcriptase enzyme.
Primers and probes
Primers and probes for MBD-2 and MeCP-2 were used according
to a recently published study (Mu ¨ller et al, 2000), primers and
probes for OR-a according to Iwao et al (2000) and for the TATA
box-binding protein (TBP; a component of the DNA-binding
protein complex TFIID as an endogenous RNA control) according
to Bieche et al (2001). Primers and probes for PR were determined
with the assistance of the computer program Primer Express
(Applied Biosystems, Foster City, CA, USA). BLASTN searches
were conducted to confirm the total gene specificity of the
nucleotide sequences chosen for the primers and probes. To
prevent amplification of contaminating genomic DNA, the probe
was placed at the junction between two exons. PR (forward-
primer): 50-TCA ACT TAC AAA ACT TCT TGA TAA CTT GC-30;
PR (reverse-primer): 50-GCC CGG GAC TGG ATA AAT G-30; PR
(probe): 50 FAM-TGA TCT TGT CAA ACA ACT TCA TCT GTA
CTG CTT GA-30TAM.
Real-time PCR amplification
PCR reactions were performed using an ABI Prism 7700 Detection
System (Applied Biosystems, Foster City, CA, USA) with a total
volume of 25ml reaction mixture containing 5ml of each
appropriately diluted RT sample (standard curve points and
patient samples), 12.5ml TaqMan Universal PCR Master Mix
(Applied Biosystems, Foster City, CA, USA), 900nM of each primer
and 250nM of the probe. The thermal cycling conditions
comprised an initial incubation at 501C for 2min, a denaturing
step at 951C for 10min and 40 cycles at 951C for 15s and at 651C
for 1min. Each experiment included a standard curve with five
cDNA concentrations, a control sample (HS578T cell-line for
MBD-2 and MeCP-2 assays, T47D cell-line for OR-a and MCF-7 for
PR), 25 patients and no template control. The standard curves were
generated using serially diluted solutions of standard cDNA
derived from the HTB-77 carcinoma cell line for MBD-2 and
MeCP-2 assays, from MCF-7 for OR-a and from T47D for PR
assays. Real-time PCR assays were conducted in triplicate for each
sample, and the mean value was used for calculation.
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To determine the transcription level, the amounts of the target and
endogenous reference were determined from the standard curve.
For value normalisation, the target amount was divided by the
endogenous reference. In order to verify the reproducibility of
each assay, the normalised control value was determined. Only
experiments in which the control value was 72 s.d. were accepted.
For determination of univariate relationships between groups,
the Mann–Whitney U-test or (for clinicopathologic features with
more than two stages) the Kruskal–Wallis test was used. Multiple
testing situations were addressed using Bonferroni correction. The
Spearman correlation analysis was used to specify relationships
between MBD2 and MeCP2, as well as between OR and PR. The
results are expressed as R values ranking from  1 (inverse
correlation) to þ1 (positive correlation), with 0 indicating no
correlation. Multiple effects and interactions of predictors were
analysed using a linear regression model for continuous dependent
variables, and a logistic regression model for dichotomous
outcome variables. The level of statistical significance was set at
Pp0.05. All analyses were performed using SPSS statistical
software. Figures are shown without outliers.
RESULTS
mRNA expression of MeCP2 and MBD2 in non-neoplastic
and neoplastic breast tissue specimens
We used the real-time PCR reaction described above to analyse
mRNA expression levels of MeCP2 and MBD2 in non-neoplastic
breast tissue (n¼11) and in breast cancer specimens (n¼57). The
expression levels were standardised using TBP expression. In both
groups, we found mRNA expression of MeCP2 and MBD2. We also
observed a strong correlation between the expression levels of
MeCP2 and MBD2 mRNA in both tissue types (r¼0.475,
Pp0.0001; Figure 1). Only MeCP2 mRNA expression levels were
found to be statistically significantly higher in breast cancer
specimens than in non-neoplastic lesions (P¼0.001; Figure 2A).
No differences in MBD2 expression levels were seen between the
two groups (P¼0.3; Figure 2B). An age difference between patients
with non-neoplastic and neoplastic lesions prompted us to use
logistic regression analysis: MeCP2 mRNA levels predicted tissue
type (non-neoplastic vs neoplastic; P¼0.045) independent of age.
mRNA expression of MeCP2 and MBD2 in relation to
clinicopathologic features in human neoplastic breast
tissue
We correlated mRNA expression levels of MeCP2 and MBD2 in
tissue specimens of breast cancer patients (n¼57) with the most
important clinicopathological features (grading, histological type
of cancer, nodal status, HER2-status, menopausal status, tumour
diameter, OR and PR status, overall survival and disease-free
survival).
We found a relationship between mRNA expression levels of
MeCP2 and OR status: MeCP2 mRNA expression levels were
statistically significantly higher in OR-positive as compared to OR-
negative breast cancer specimens (P¼0.005; Figure 3A). No
differences were observed in MBD2 mRNA expression levels.
To study whether the same is true for non-neoplastic tissue,
we analysed mRNA expression of OR and PR in the non-neoplastic
tissue group (n¼11). We grouped the samples according to
high OR or PR expression. The ‘OR mRNA high’ group
demonstrated significantly higher MeCP2 mRNA levels than did
the ‘OR mRNA low’ group (P¼0.017; Figure 3B), whereas MBD2
levels did not differ between these groups (data not shown).
Progesterone levels had no impact on MBD2 or MeCP2 expression
(data not shown).
Looking solely at grade I and grade III breast cancer lesions, we
observed a visible trend towards lower levels of MeCP2 in grade III
lesions as compared to grade I lesions (Figure 4). This association
was not statistically significant, which may be due to the small
sample size of the two analysed groups. Investigation of the other
clinicopathologic features and mRNA expression of MeCP2 and
MBD2 showed no statistically significant differences (data not
shown).
MeCP2/TBP


















Figure 1 Expression of MeCP2 mRNA in non-neoplastic (n¼11) and
neoplastic (n¼57) breast tissue specimens. Expression levels were
analysed using a quantitative real-time PCR method, as described in
Materials and Methods. Expression levels were standardised using TBP
expression. A strong correlation between the expression levels of MeCP2
and MBD2 mRNA was seen in both tissue types.



































Figure 2 (A) Expression of MeCP2 mRNA in non-neoplastic (n¼11)
and neoplastic (n¼57) breast tissue specimens. Expression levels were
analysed using a quantitative real-time PCR method, as described in
Materials and Methods. Expression levels were standardised using TBP
expression. Outliers were excluded. (B) Expression of MBD2 mRNA in
non-neoplastic (n¼11) and neoplastic (n¼57) breast tissue specimens.
Outliers were excluded.
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yMeCP2 mRNA expression predicts OR mRNA expression
in human non-neoplastic and neoplastic breast tissue
specimens
A very strong correlation between OR and PR status (identified
immunohistochemically and/or biochemically) and the OR and PR
mRNA expression in breast cancer specimens measured by RT–
PCR was seen (r¼0.690, Pp0.0001; r¼0.714, Pp0.0001, respec-
tively).
A relationship between OR and PR is widely known to exist. In
our analysis, we found this strong correlation between OR and PR
in neoplastic tissue (r¼0.650, Pp0.0001, respectively), and a
statistically nonsignificant trend in non-neoplastic tissue.
To address whether MeCP2 or MBD2 predicts OR mRNA
independent of PR, age, interaction of MBD2 and MeCP2 (see
Figure 1; expressed by a multiplication of MeCP2 with MBD2
values) and tissue type (non-neoplastic or neoplastic), we used
linear regression: MeCP2 independently predicted OR mRNA
expression (P¼0.003). Using PR mRNA expression as an outcome
variable, only OR mRNA remains as a statistically significant
predictor.
DISCUSSION
So far only few studies have analysed mRNA expression of MBD2
and MeCP2 in human non-neoplastic and neoplastic tissues (Kanai
et al, 1999; Mu ¨ller-Tidow et al, 2001; Billard et al, 2002). This is a
new report focusing solely on the expression behaviour of MBD2
and MeCP2 in non-neoplastic and neoplastic breast tissues.
We were able to demonstrate for the first time a statistically
significant correlation in the mRNA expression of MBD2 and
MeCP2. Interestingly, we observed only a reduction in MeCP2
mRNA in non-neoplastic tissue as compared to breast cancer
tissue. With regard to MBD2 mRNA expression, we did not find
different expression levels. We have no explanation for the
phenomenon that only MeCP2 is dysregulated, while both MBDs
obviously correlate in their expression behaviour. Our findings
also contradict the published data, because, as mentioned above,
only a reduction in MBD2 has been detected in human neoplasia
(Kanai et al, 1999; Mu ¨ller-Tidow et al, 2001; Billard et al, 2002).
There are several reasons that may explain the different findings.
First of all, two studies (Kanai et al, 1999; Mu ¨ller-Tidow et al, 2001)
did not exclusively use breast tissue, as we did in our
investigations. As we know from other studies, the expression
levels of MeCP2 differ depending on the tissue type analysed
(Meehan et al, 1992; Tate et al, 1996). Therefore, the use of a panel
of tumour tissues is more likely to produce a different expression
profile than is the use of only one tissue type. For the same reason,
a comparison of digestive cancer tissue and breast cancer tissue
might well be problematic. A second explanation may be the
methodological differences between our study and that of Billard
et al (2002), who used a competitive RT–PCR method to measure
the absolute amount of an mRNA sample, not related to the
amount of another control mRNA.
This study also reports for the first time a strong association
between OR status and MeCP2 mRNA expression in human breast
tissue specimens. So far only Billard et al (2002) published a report
dealing with MBD2 and MeCP2 mRNA expression in human breast
tissue, but they did not find any correlation between OR status and
MeCP2 expression level. As mentioned above, the methodological
differences and the small sample size used in their study are
possible reasons for the different findings.
We found this strong association between high levels of MeCP2
mRNA and OR positivity not only at the protein level of OR
(immunohistochemically and/or biochemically determined) but
also at the mRNA level of OR (using real-time PCR). As a second
step, we aimed to exclude all possible influences on OR expression
in order to check whether the expression level of MeCP2 is
independently associated with OR status in human breast cancer.
We also included the non-neoplastic tissues to address the
question of whether this is a general phenomenon in breast tissue
or whether it is true only for breast cancer tissue. For this reason,
we designed a statistical linear regression model, which included
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Figure 3 (A) Expression of MeCP2 mRNA in OR pos/neg neoplastic
breast tissue specimens (n¼57). Expression levels were analysed using a
quantitative real-time PCR method, as described in Materials and Methods.
Expression levels were standardised using TBP expression. Outliers were
excluded. (B) Expression of MeCP2 mRNA in non-neoplastic (n¼11)
breast tissue specimens as a function of OR mRNA expression. Outliers
were excluded.
10 25 N =
Neoplastic breast tissue specimens 
















Figure 4 Expression of MeCP2 mRNA in grade I (n¼25) and grade III
(n¼10) breast cancer lesions. Expression levels were analysed using a
quantitative real-time PCR method, as described in Materials and Methods.
Expression levels were standardised using TBP expression. Outliers were
excluded.
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yPR mRNA expression and age (both known to have a strong
influence on OR mRNA expression), MeCP2, MBD2 mRNA
expression and MeCP2 and MBD2 interactions (expressed as the
product of both values). Using this model, we observed that the
expression level of MeCP2 mRNA is independently associated with
the expression level of OR. Using PR mRNA expression as an
outcome variable, only OR mRNA remains as a statistically
significant predictor. For several reasons, we speculate that MeCP2
– as one of the most important mediators of the epigenetic signal –
is regulated by OR and therefore plays a key role in the
differentiation processes in human breast tissues:
First of all, it is known that MeCP2 plays a central role in cellular
differentiation and development: MeCP2 is not expressed during
proliferation or in vitro differentiation of the embryonic stem cells,
but becomes important at the organ differentiation stage (Li et al,
1992; Tate et al, 1996). Furthermore, a significant upregulation of
MBD2 and MeCP2 mRNA during prenatal development of the
human mammary gland has been reported (Billard et al, 2002).
From these findings concerning the behaviour of MeCP2 during
embryonic development, it also seems to be plausible that higher
levels of MeCP2 mRNA can be found in better-differentiated
human breast cells, indicated by OR positivity.
Recently, an indication of the role of MeCP2 in human
development was also provided by linking mutations in the
MeCP2 gene to the human neurodevelopmental disorder Rett
syndrome (RTT) (Amir et al, 1999). Rett syndrome is thought to
stem from excessive transcriptional noise due to the failure of
MeCP2 to silence genes (Amir and Zoghbi, 2000; Clayton-Smith
et al, 2000). Other studies also reported a change in the expression
level of various genes associated with MeCP2 mutations (Cheadle
et al, 2000; Traynor et al, 2002).
Anti-MeCP2 staining reveals a uniform pattern, suggesting that
5-mC is distributed throughout the genome, and that binding of
10
6 MeCP2 molecules per cell nucleus may suppress transcrip-
tional noise rather than specific genes (Nan et al, 1997).
As we know from preliminary studies in our laboratory with the
OR-positive breast cancer cell line MCF-7, OR mRNA is down-
regulated after treatment with oestrogen. This downregulation of
OR mRNA is followed by a downregulation of MeCP2 mRNA,
indicating a direct regulation of MeCP2 mRNA via the OR pathway
(data not shown).
Another important finding – that fits well into our observations
– suggests that a complex formation between DNMT1 and MeCP2
is necessary for maintenance of methylation in vivo and was
recently reported by Kimura and Shiota (2003).
Overall, we speculate that during differentiation processes in
human breast tissues, OR induces the expression of MeCP2, which
consequently binds to methylated DNA sequences producing a
more compact chromatin state because of interaction with the
histone deacetylases and diminishing transcriptional noise. The
complex formation between DNMT1 and MeCP2 is also necessary
for maintenance of methylation in vivo. This also guarantees a
transfer of the overall methylation pattern to the daughter cells
during mitosis, producing a stable differentiated type of tissue.
This hypothesis is also supported by the finding that we detected a
visible trend towards lower levels of MeCP2 in grade III lesions as
compared to grade I lesions (Figure 4), even though this
association is not statistically significant. A decrease in MeCP2/
DNMT1 complexes may cause a decrease in DNA methylation and
subsequently dedifferentiation of the tumour. Such a connection
between DNA hypomethylation in special regions (chromosomes 1
and 16) and tumour dedifferentiation has been shown for breast
cancer (Tsuda et al, 2002). DNA hypomethylation in general seems
to play a central role in carcinogenesis, possibly promoted by
chromosomal instability (Eden et al, 2003; Gaudet et al, 2003).
This study shows for the first time that a strong association
between OR status and mRNA expression of the methyl-CpG-
binding protein MeCP2, known as a mediator of the epigenetic
signal, exists in human breast tissues. Whether MeCP2 is directly
involved in the OR pathway or its upregulation is only a general
phenomenon of differentiation in breast tissue represented by the
expression of OR remains to be further analysed.
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